source · text/markdown
source_a51902724f274e3b
sha256 7e84702c33faac20499f2f2eba519f186b503fd24a4e87ccc3b1282b21dd6c5c
by researka:v2 · 2026-05-28 17:56:04.207940+04:00
This synthesis tests the thesis that evidence for CGM glucose variability is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes cgm glucose variability as an aging-related intervention across 51 included source papers and 3303 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 35 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 510 cross-study disagreements across the evidence base. Positive study-level signals concentrate in cardiometabolic, null signals in contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics, and negative signals in cardiometabolic. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that cgm glucose variability remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "58c4cc92-a3c1-49d6-9165-711a759d4415",
"title": "Research Synthesis: Cgm Glucose Variability \u2014 full paper"
}